Maravai LifeSciences Holdings, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Maravai LifeSciences Holdings, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
0.7×Over the last 3 years its own operating cash paid for 70% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Higher than 66% of Healthcare companies in United States.
Cash Locked Ratio
$34For every $100 of sales, $34 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $16 tied up three years earlier.
More money tied up than 72% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 79%
Sales fell 79% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-79% / -66%In 3 years sales changed by -79% while total assets changed by -66%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-10.6×Operating cash was negative last year, while some debt falls due within a year.
Higher than 54% of Healthcare companies in United States.
Cash Cushion Ratio
−6%Debt, after subtracting cash, equals 6% of its market value (net debt).
Lower than 75% of Healthcare companies in United States.
Tangible Assets Ratio
64%Of every $100 the company owns, $64 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 67% of Healthcare companies in United States.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than 83% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Maravai LifeSciences Holdings, Inc. made a loss over the last year. Maravai LifeSciences Holdings, Inc. owes $0.41 for every $1 it owns. Maravai LifeSciences Holdings, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossMaravai LifeSciences Holdings, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
12.80The share price is 12.80 times Maravai LifeSciences Holdings, Inc.'s book value per share, higher than 89% of Healthcare companies in United States.
Market cap
$2.6 BThe total market value of all of Maravai LifeSciences Holdings, Inc.'s shares at today's price (share price × number of shares), larger than 79% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$205 MWhat Maravai LifeSciences Holdings, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.55Net worth divided by the number of shares. The share price of $7.07 is 12.8 times this, which is the P/B above.
Return on equity (ROE)
-33.0%Maravai LifeSciences Holdings, Inc. lost 33.0% of its shareholders' money over the last year, higher than 59% of Healthcare companies in United States.
Owes vs Owns
0.41×Maravai LifeSciences Holdings, Inc. owes $0.41 for every $1 it owns (low), lower than 51% of Healthcare companies in United States.
Dividend yield
NoneMaravai LifeSciences Holdings, Inc. does not currently pay a dividend.
Revenue growth
-28%Revenue fell 28% in the year to Dec 2025, and shrank 41% a year on average over 3 years.
Profit growth
LossMaravai LifeSciences Holdings, Inc. made a loss in each of the last two years.
Profit margin
-70.4%Maravai LifeSciences Holdings, Inc. lost $70 for every $100 of revenue.
Interest cover
Not coveredMaravai LifeSciences Holdings, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtMaravai LifeSciences Holdings, Inc. had $148 M more debt than cash (net debt) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Maravai LifeSciences Holdings, Inc.: $2.6 B ÷ $205 M (30 Jun 2026) = 12.8.
What is Maravai LifeSciences Holdings, Inc.'s return on equity?
Maravai LifeSciences Holdings, Inc. lost 33.0% of its shareholders' money over the last year, higher than 59% of Healthcare companies in United States.
How much does Maravai LifeSciences Holdings, Inc. owe compared with what it owns?
Maravai LifeSciences Holdings, Inc. owes $0.41 for every $1 it owns (low), lower than 51% of Healthcare companies in United States.
Does Maravai LifeSciences Holdings, Inc. pay a dividend?
No. Maravai LifeSciences Holdings, Inc. does not currently pay a dividend.
Is Maravai LifeSciences Holdings, Inc.'s revenue growing?
Revenue fell 28% in the year to Dec 2025, and shrank 41% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.